Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

NNASDAQ:CGEM
9.50
USD
-0.78
(-7.59%)
-3.32EPS
996.23MMarket Cap
Mar 17Next Earn

Total Valuation

USD

As of September 30, 2026, Cullinan Therapeutics, Inc. carries a market capitalization of 996.23M, placing it among publicly traded companies globally. Its enterprise value stands at 708.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap996.23M
Enterprise Value708.66M

Important Dates

Cullinan Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 17, 2027.

Earnings Date3/17/2027

Share Statistics

As of September 30, 2026, Cullinan Therapeutics, Inc. has 64.90M shares outstanding.

Shares Outstanding64.90M

Valuation Ratios

These figures are as of September 30, 2026.

PB Ratio3.54
P/TBV Ratio3.54
P/FCF Ratio-5.69
P/OCF Ratio-5.69

Financial Position

As of September 30, 2026, Cullinan Therapeutics, Inc. maintains a current ratio of 7.43, meaning it holds 7.4x the short-term assets needed to cover near-term liabilities.

Current Ratio7.43
Quick Ratio7.22
Debt / Equity0.71
Debt / EBITDA-0.01

Financial Efficiency

Over the twelve months ended September 30, 2026, Cullinan Therapeutics, Inc. posted a negative return on equity (ROE) of -55.54, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -50.44, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 109.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-55.54
Return on Assets (ROA)-50.44
Employee Count109.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Cullinan Therapeutics, Inc.'s stock has gained approximately 11.11% over the past 52 weeks. The 50-day moving average sits at 15.62, while the 200-day moving average is 15.81.

52-Week Price Change11.11%
50-Day Moving Average15.62
200-Day Moving Average15.81

Income Statement

USD

Over the twelve months ended September 30, 2026, Cullinan Therapeutics, Inc. generated - - in revenue and converted that into -203.47M in net income, yielding earnings per share of -3.32. EBITDA reached -218.52M, while operating income came in at -218.81M.

Operating Income-218.81M
Pretax Income-203.47M
Net Income-203.47M
EBITDA-218.52M
EBIT-218.81M
Earnings Per Share (EPS)-3.32

Balance Sheet

USD

As of September 30, 2026, Cullinan Therapeutics, Inc. holds 289.57M in cash and equivalents against 2.00M in total debt, resulting in a net debt position of -88.26M. Total book value stands at 281.28M, with working capital of 258.02M providing operational flexibility.

Cash & Cash Equivalents289.57M
Total Debt2.00M
Net Debt-88.26M
Equity (Book Value)281.28M
Book Value Per Share4.33
Working Capital258.02M

Cash Flow

USD

Cullinan Therapeutics, Inc. produced -165.45M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -11,000.00 in capital expenditures, free cash flow totaled -165.47M - equivalent to -2.70 per share.

Operating Cash Flow-165.45M
Capital Expenditures-11,000.00
Free Cash Flow-165.47M
FCF Per Share-2.70

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -17.57: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.33, meaning Cullinan Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-0.33
FCF Yield-17.57

Scores

As of September 30, 2026, Cullinan Therapeutics, Inc. has an Altman Z-Score of 9.99, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score9.99